Darrin Stuart Selected Research

RAF265

9/2015	Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma.
3/2011	Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Darrin Stuart Research Topics

Disease

6	Neoplasms (Cancer) 09/2015 - 04/2009
5	Melanoma (Melanoma, Malignant) 09/2015 - 03/2011
2	Neoplasm Metastasis (Metastasis) 03/2015 - 11/2014
1	Brain Neoplasms (Brain Tumor) 11/2014
1	Carcinogenesis 04/2014
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 04/2014
1	Keratoacanthoma 04/2014

Drug/Important Bio-Agent (IBA)

2	RAF265IBA 09/2015 - 03/2011
2	Proteins (Proteins, Gene)FDA Link 11/2014 - 03/2012
2	DNA (Deoxyribonucleic Acid)IBA 04/2014 - 03/2011
1	Proto-Oncogene Proteins B-rafIBA 09/2015
1	Dacarbazine (DIC)FDA LinkGeneric 03/2015
1	LigandsIBA 03/2015
1	Messenger RNA (mRNA)IBA 11/2014
1	VemurafenibIBA 04/2014
1	Mitogen-Activated Protein KinasesIBA 04/2014
1	2- amino- 7- (4- fluoro- 2- (6- methoxypyridin- 2- yl)phenyl)- 4- methyl- 7,8- dihydropyrido(4,3- d)pyrimidin- 5(6H)- oneIBA 03/2012
1	Protein CIBA 03/2012
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2011
1	Annexin A5IBA 03/2011
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 03/2011
1	Glucose (Dextrose)FDA LinkGeneric 03/2011
1	ThymidineIBA 03/2011
1	Biomarkers (Surrogate Marker)IBA 03/2011
1	Phosphotransferases (Kinase)IBA 04/2009

Therapy/Procedure

3	Therapeutics 03/2015 - 04/2009
1	Aftercare (After-Treatment) 03/2011